ALDERIA INTELLIGENCE
← All signals
PubMed21 Apr 2026Nature medicine● 2/10i

Low-plastic diet and urinary levels of plastic-associated phthalates and bisphenols: the randomized controlled PERTH Trial.

Harray AJ, Lucas AD, Herrmann SE, Vlaskovsky PS, Elagali A et al.

A 7-day low-plastic diet reduced urinary levels of phthalates and bisphenols by 37.5% to 59.7% compared to control in 60 Australian adults. Randomized controlled trial with observational cohort of 211 participants measuring plastic-associated chemical exposure through food packaging and personal care products. This provides first controlled evidence that short-term dietary interventions can measurably reduce plastic chemical exposure, potentially relevant for cardiometabolic health given observed negative associations with metabolic biomarkers.

Strategic Signal

This environmental health finding has limited direct relevance to cardiometabolic pharma companies unless plastic chemical exposure emerges as a significant confounding factor in metabolic disease trials or regulatory discussions. The data may influence broader public health messaging around processed food consumption, which could indirectly affect patient populations in diabetes and obesity trials, but represents a tangential research area rather than core therapeutic development.

Other

Original Abstract

The everyday use of plastic products exposes us to plastic-associated chemicals (PACs), which have been associated with risks to human health. We present the results of the Plastic Exposure Reduction Transforms Health Trial, with an observational cohort of 211 Australian participants and a 7-day pilot randomized controlled trial in 60 participants. Intervention groups received combinations of plastic-free kitchenware, low-plastic personal-care products and food sourced from more than 100 producers that minimized all plastic touchpoints from paddock to plate, while the control group received no intervention. The primary trial outcome was a reduction in urinary plastics-associated chemicals levels. In the cohort study, highly processed, plastic-packaged and canned foods were important modifiable factors for urinary PAC metabolite levels. Additionally, we observed negative associations between cardiometabolic biomarkers and higher urinary di(2-ethylhexyl) phthalate metabolites. Our randomized controlled dietary intervention maintained participants' daily energy intake while decreasing plastic exposure (P < 0.001) and urinary levels of mono-n-butyl phthalate, monobenzyl phthalate and bisphenol A by 37.5% (95% confidence interval (CI): -55.6, -12.0; P = 0.007), 53.5% (95% CI: -72.7, -20.6; P = 0.005) and 59.7% (95% CI: -82.5, -6.87; P = 0.033), respectively. Intervention groups provided with foods that had minimal to no contact with plastic had the broadest effect on PAC excretion, and replacing low-plastic personal-care products alone led to an independent decrease in urinary mono-n-butyl phthalate, compared to no intervention. Despite constant plastic exposures, limiting food plastics touchpoints decreases select PACs in 7 days. Australian and New Zealand Clinical Trials Registry: ACTRN12622001252707 .

Related signals

Strategic Signal

FDA19 Mar 2026Supplemental Approval: Efficacy [Priority Review]High impact● 9/10i

FDA Approves Imcivree (Setmelanotide): Supplemental Approval: Efficacy [Priority Review]

FDA approved a supplemental application for Imcivree (setmelanotide, Rhythm) on March 19, 2026, under priority review. This represents an efficacy-based label expansion for the melanocortin-4 receptor agonist, which was initially approved for rare genetic obesity disorders. Rhythm gains additional indication breadth in the specialized rare obesity market, where treatment options remain extremely limited. The priority review designation signals FDA recognition of significant unmet medical need in the expanded patient population.

Weight lossOtherRhythm

Strategic Signal

Clinical Trial20 Mar 2026Phase 3● 7/10i

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Orforglipron is being tested in women with stress urinary incontinence who have obesity or overweight in two phase 3 studies under a master protocol. The trials will enroll 1,000 participants with 58-week follow-up, comparing daily oral orforglipron to placebo. This represents a novel indication expansion for Eli Lilly's small-molecule GLP-1 beyond diabetes and weight management, targeting a large underserved population where weight loss could provide therapeutic benefit. This marks the first major GLP-1 trial in urological conditions, potentially opening a new market segment.

GLP-1OtherEli Lilly

Strategic Signal

PubMed21 Apr 2026JAMA● 6/10i

Obesity and Cancer: A Translational Science Review.

People with obesity who lost more than 10% of body weight through bariatric procedures or GLP-1 receptor agonists had modest reductions in obesity-associated cancer incidence, with absolute risk reductions of -0.02% to -0.5%. Observational analysis of 30,318 bariatric patients and 1,651,452 GLP-1 users. This provides the first large-scale evidence linking GLP-1-mediated weight loss to cancer risk reduction, potentially expanding the value proposition beyond diabetes and cardiovascular outcomes. The modest effect sizes suggest cancer prevention benefits may require substantial sustained weight loss.

GLP-1Weight lossOtherNovo NordiskEli Lilly

Strategic Signal

EMA14 Apr 2026EC Decision — New Marketing Authorisation● 6/10i

EMA: EC Decision — New Marketing Authorisation — Pavblu (aflibercept)

The European Commission approved aflibercept (Pavblu, Amgen) for neovascular age-related macular degeneration, visual impairment from retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization on April 14, 2026. This represents a new marketing authorization following CHMP positive opinion in January 2025. The approval establishes Amgen's entry into the competitive anti-VEGF ophthalmology market, challenging established players Regeneron/Bayer (Eylea) and Roche (Lucentis/Vabysmo) across multiple retinal indications.

Weekly briefing

Key signals, decoded for pharma executives and investors. Free, every week.

Questions? Book a consultation →